115 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
Inc. in positions of increasing responsibility across legal and regulatory affairs functions. Dr. Milligan served in the United States Army Medical
8-K
SYRE
Spyre Therapeutics Inc.
15 May 24
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
7:40am
of Product Development Regulatory for Genentech, Inc., and, from 2002 to 2012, she was at Amgen Inc. in positions of increasing responsibility across
8-K
EX-10.1
SYRE
Spyre Therapeutics Inc.
25 Apr 24
Unregistered Sales of Equity Securities
4:21pm
no responsibility for, and provides no assurance as to the reliability of, any other information that others may provide to the Stockholder.
(f
POS AM
1ee9omm62cl23v8gya
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
424B3
dqjt275o be
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-10.1
gbl6y7o9sqr8hb 518c
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
egnxyj 20ebtitiig
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
4tv 8m9beq
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
p1gtt
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-14.1
g42x1e
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
S-8
EX-99.2
g5mp9y2yv311svjxv
22 Dec 23
Registration of securities for employees
5:00pm
S-8
EX-99.1
ilg3zdg otxp7m8w9
22 Dec 23
Registration of securities for employees
5:00pm